TheracosBio extends collaboration with Mark Cuban Cost Plus Drug Company, offering BRENZAVVY® directly to healthcare businesses via Cost Plus Drugs Marketplace. BRENZAVVY is a cost-effective SGLT2 inhibitor for type 2 diabetes, reducing medication costs and improving accessibility. Available at $47.85 per 30-tablet bottle, it aims to enhance patient care by simplifying procurement. The initiative addresses medication adherence challenges, with BRENZAVVY showing efficacy in clinical studies, including patients with stage 3 chronic kidney disease.
TheracosBio today announced that it is extending its collaboration with the Mark Cuban Cost Plus Drug Company. Under the partnership, BRENZAVVY® (bexagliflozin) is available directly to healthcare businesses under the Cost Plus Drugs Marketplace program.
BRENZAVVY represents a new approach to diabetes care. It is the first affordably priced, once-daily SGLT2 inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The low cost of BRENZAVVY – the list price is 90% below other medicines in its class — allows for expanded access for the uninsured and improves care for those with insurance by eliminating the hassles of insurance-company utilization management and cost-sharing. Pharmacies, hospitals and other healthcare businesses can now purchase the medicine through a Cost Plus Drugs site designed for businesses — business.costplusdrugs.com — for $47.85 per each 30 tablet bottle.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We launched BRENZAVVY in 2023 by making it available directly to patients at a transparent, low price through Mark Cuban Cost Plus Drugs online pharmacy and have been thrilled with the results,” said Brian Connelly, President and CEO of TheracosBio. “Through the new Cost Plus Drugs Marketplace, we are excited to provide affordably priced BRENZAVVY to healthcare businesses who are on the frontline in helping their patients and customers manage diabetes. This expansion of our collaboration should make it easier than ever for patients to access BRENZAVVY, whether online or through their healthcare provider, clinic, or pharmacy.”
“Mark Cuban Cost Plus Drug Company has recently expanded its mission to make medications more affordable for healthcare businesses with the launch of the Cost Plus Drugs Marketplace,” said Dr. Alex Oshmyansky, CEO and Co-founder of Mark Cuban Cost Plus Drug Company. “This new platform provides healthcare businesses, including pharmacies, hospitals, surgery centers, and other healthcare providers, with access to a wide array of prescription and over-the-counter medications. Sourced from NABP-accredited suppliers, these drugs are offered at competitive prices to ensure that healthcare businesses can procure essential medications cost-effectively.”
Approximately 1 in 10 adults in the United States have type 2 diabetes, but suboptimal adherence to medication is common. A study of adherence among adults in the Medicare Part D database, published in the journal Clinical Therapeutics, estimated that 35.1% of patients were non-adherent to oral hypoglycemic agents. Cost-related nonadherence was reported by 17.6% of diabetic adults in the 18- to 64-year-old age group in a 2022 study published in Diabetes Care.
BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. Phase 3 clinical studies have shown BRENZAVVY significantly reduces hemoglobin A1c and fasting blood sugar after 24 weeks, either as a monotherapy, in combination with metformin, or as an add-on to standard-of-care treatment consisting of a variety of regimens, including metformin, sulfonylureas, insulin, DPP4 inhibitors or combinations of these agents. Although BRENZAVVY is not approved for weight or blood pressure reduction, modest decreases in both weight and blood pressure have been observed in the clinical program.
BRENZAVVY is available as 20 mg oral tablets recommended to be taken once daily, in the morning with or without food. BRENZAVVY is contraindicated in patients who are hypersensitive to bexagliflozin or any other ingredient in the BRENZAVVY tablet. The most common side effects of taking BRENZAVVY include female genital mycotic infections, urinary tract infections, and changes in urination, but more serious side effects are possible (see below, Important Safety Information about BRENZAVVY).
BRENZAVVY treatment can be initiated in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m2. Patients with eGFR between 30 and 59 mL/min/1.73 m2 are said to be in stage 3 chronic kidney disease. BRENZAVVY was the first SGLT2 inhibitor shown in a randomized, controlled clinical trial to be effective in adults with type 2 diabetes and stage 3 (3a + 3b) chronic kidney disease.
Source: Bio Space